These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Detection of antibody to LAV/HTLV-III in sera from hemophiliacs in China.
    Author: Zeng Y, Fan J, Zhang Q, Wang PC, Tang DJ, Zhon SC, Zheng XW, Liu DP.
    Journal: AIDS Res; 1986 Dec; 2 Suppl 1():S147-9. PubMed ID: 3103638.
    Abstract:
    Using ELISA, Western blots and immunofluorescence techniques, we identified seropositivity for lymphadenopathy-associated virus/human lymphotropic virus-III (LAV/HTLV-III) in 4 of 18 hemophiliacs and 1 AIDS patient. The four seropositive patients had received factor VIII prepared by Armour Company. The hemophiliacs are all asymptomatic. Given this documentation of introduction of LAV/HTLV-III into China, a national surveillance program is underway. The detection of human immunodeficiency virus (HIV) in hemophiliacs treated with factor VIII has prompted the Government of China to institute a national surveillance program. An earlier survey of 310 healthy individuals and leukemia patients from 8 provinces failed to yield any sera positive for antibodies to HIV. However, given the documented high seroprevalence rate among hemophiliacs, the sera of 28 Chinese hemophiliacs and 1 acquired immunodeficiency syndrome (AIDS) patient were analyzed by enzyme-linked immunosorbent assay (ELISA). Antibodies to HIV were detected in the AIDS patient and in 4 of the hemophiliacs. All 4 of the seropositive cases were from a group of 18 hemophiliacs who had received factor VIII produced by the US-based Armour Company. This suggests that HIV infection was transmitted to China from the US via blood products at a frequency of 22%. At the time of the study, all 4 seropositive hemophiliacs were asymptomatic.
    [Abstract] [Full Text] [Related] [New Search]